Publications by authors named "E Missiaglia"
The RHOA G17V mutation is highly recurrent in follicular helper T-cell (TFH) lymphoma of the angioimmunoblastic type (AITL) (60-70% of cases) and frequently associated with mutations in other T-cell receptor signaling genes, including CD28. Here, we sought to elucidate how RHOA and CD28 variants may work in concert to sustain T-cell activation by generating stable Jurkat T-cell lines expressing wild type (wt) RHOA or RHOA G17V with wt CD28 or CD28 T195P. Concomitant expression of RHOA G17V and CD28 T195P induced significantly higher levels of interleukin 2 (IL-2) production and NFAT and AP1 transcriptional activities than either variant alone upon T-cell activation with agonistic anti-CD3 and anti-CD28 antibodies.
View Article and Find Full Text PDFSomatic variant testing through next-generation sequencing (NGS) is well integrated into Swiss molecular pathology laboratories and has become a standard diagnostic method for numerous indications in cancer patient care. Currently, there is a wide variation in reporting practices within our country, and as patients move between different hospitals, it is increasingly necessary to standardize NGS reports to ease their reinterpretation. Additionally, as many different stakeholders-oncologists, hematologists, geneticists, pathologists, and patients-have access to the NGS report, it needs to contain comprehensive and detailed information in order to answer the questions of experts and avoid misinterpretation by non-experts.
View Article and Find Full Text PDFArticle Synopsis
- Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a diverse and challenging type of cancer that often has poor outcomes, especially in younger patients lacking the SMARCB1 protein.
- Research indicated that human and mouse PTCL-NOS exhibit similar DNA changes, including the hypermethylation of T-cell genes and the hypomethylation of myeloid development genes, contributing to a complicated tumor ecosystem.
- A study found that histone deacetylase inhibitors (HDACi), like SAHA, can effectively treat PTCL-NOS by modifying the tumor's microenvironment and improving immune function, paving the way for potential combination therapies.
Article Synopsis
- Immunotherapies have shown limited success in treating nodal peripheral T-cell lymphomas (PTCLs) due to a poor understanding of their immune responses.
- Researchers conducted detailed analyses of the immune tumor microenvironment (TME) in various PTCL samples, revealing a higher presence of regulatory T cells and exhausted CD8+ T cells.
- The study found that high levels of CD39 expression on T cells are associated with worse patient outcomes, suggesting it as a potential new prognostic factor and target for treatment.
Primary bone lymphoma (PBL) is rare and mostly represented by diffuse large B-cell lymphomas (DLBCL). Follicular lymphoma (FL), albeit commonly disseminating to the bone marrow, rarely presents primarily as bone lesions. Here, we studied 16 patients (12 men:4 women, median age 60 years) who presented with bone pain and/or skeletal radiologic abnormalities revealing bone FL.
View Article and Find Full Text PDF